Skip to Main Content

Author Details

Hua Li
University of California san francisco
2013
29
17
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36857322Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.PLoS One2023
35158773NSAIDs Overcome <i>PIK3CA</i> Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.Cancers (Basel)2022
35402542Melatonin Attenuates Dasatinib-Aggravated Hypoxic Pulmonary Hypertension via Inhibiting Pulmonary Vascular Remodeling.Front Cardiovasc Med2022
35929989STAT3 Activation as a Predictive Biomarker for Ruxolitinib Response in Head and Neck Cancer.Clin Cancer Res2022
34261774Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2021
33614939Clinical trials optimizing investigator and self-collection of buccal cells for RNA yield.Laryngoscope Investig Otolaryngol2021
34546978Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer.JCI Insight2021
34779417Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma.J Clin Invest2021
32470167Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia.J Med Virol2020
30683736Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer.J Exp Med2019
34522245Downregulation of long non-coding RNA B-Raf proto-oncogene-activated non-coding RNA reverses cisplatin resistance in laryngeal squamous cell carcinoma.Arch Med Sci2019
31661135Gene targets of sulforaphane in head and neck squamous cell carcinoma.Mol Med Rep2019
31345392ATR inhibition sensitizes HPV<sup>-</sup> and HPV<sup>+</sup> head and neck squamous cell carcinoma to cisplatin.Oral Oncol2019
30770370Correction: Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.Cancer Res2019
29792310BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC.Cancer Res2018
29440171Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.Cancer Res2018
27986750Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV<sup>+</sup> Patients.Clin Cancer Res2017
25982282Frequent promoter hypermethylation of PTPRT increases STAT3 activation and sensitivity to STAT3 inhibition in head and neck cancer.Oncogene2016
26676751Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.Cancer Res2016
27267892STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma.Cancer Prev Res (Phila)2016
26685214Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts.Mol Cancer Res2016
27004400MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin.Oncotarget2016
26138066Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies.Clin Cancer Res2015
26267899Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.PLoS One2015
26181029Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.JAMA Oncol2015
24425785Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.Mol Cancer Res2014
24395800Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer.Proc Natl Acad Sci U S A2014
24395569Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.Mol Med2014
23619167Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.Cancer Discov2013
  • 1 - 29 of 29

Recommended Authors

Kara M Ruicci
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2017
Number of shared co-authors 0
Morgan Black
Schulich School of Medicine and Dentistry, Western University
Career Start Year 2014
Number of shared co-authors 0
Chao Liu
Xiangya Hospital, Central South University
Career Start Year 2013
Number of shared co-authors 1
Shuling Ren
Beijing Friendship Hospital, Capital Medical University
Career Start Year 2013
Number of shared co-authors 1
Takahito Fukusumi
Osaka University Graduate School of Medicine
Career Start Year 2012
Number of shared co-authors 1
Theresa Guo
Moores Cancer Center, University of California
Career Start Year 2012
Number of shared co-authors 3
Jeff P Bruce
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2010
Number of shared co-authors 0
Zhiyong Wang
Moores Cancer Center, University of California San Diego
Career Start Year 2008
Number of shared co-authors 12
Juan L Callejas-Valera
Cancer Biology Research Center
Career Start Year 2008
Number of shared co-authors 0
Pinaki Bose
Cumming School of Medicine, University of Calgary
Career Start Year 2008
Number of shared co-authors 0
Sophia Bornstein
Cornell University
Career Start Year 2005
Number of shared co-authors 2
Jalna Meens
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 0
Sabrina Daniela da Silva
Jewish General Hospital
Career Start Year 2004
Number of shared co-authors 0
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 8
Natalia Issaeva
The University of North Carolina at Chapel Hill
Career Start Year 2002
Number of shared co-authors 3
Wei Shi
Research Institute, Princess Margaret Cancer Centre
Career Start Year 2002
Number of shared co-authors 1
Ezra E W Cohen
university of california san diego Health System
Career Start Year 2001
Number of shared co-authors 9
Anthony C Nichols
University of Western Ontario
Career Start Year 2001
Number of shared co-authors 3
Robert I Haddad
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2001
Number of shared co-authors 11
Loris De Cecco
Fondazione IRCCS Istituto Nazionale dei Tumori
Career Start Year 2000
Number of shared co-authors 0
Rifat Hasina
University of Chicago Medicine
Career Start Year 1999
Number of shared co-authors 1
David Neil Hayes
Center for Cancer Research, University of Tennessee Health Science Center
Career Start Year 1999
Number of shared co-authors 12
Zhong Chen
National Institute on Deafness and Other Communication Disorders
Career Start Year 1995
Number of shared co-authors 1
Mitchell J Frederick
Baylor College of Medicine
Career Start Year 1995
Number of shared co-authors 3
Fei-Fei Liu
Princess Margaret Cancer Centre, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 3
Ravindra Uppaluri
Brigham and Women's Hospital
Career Start Year 1988
Number of shared co-authors 5
Jeffrey N Myers
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 8
Wendell G Yarbrough
University of North Carolina at Chapel Hill
Career Start Year 1986
Number of shared co-authors 7
Ruud H Brakenhoff
Vrije Universiteit Amsterdam
Career Start Year 1986
Number of shared co-authors 0
Carter Van Waes
National Institute of Deafness and Other Communication Disorders
Career Start Year 1984
Number of shared co-authors 4

Collaborators

Jennifer R Grandis
University of California san francisco
Co-authored papers 26
Daniel E Johnson
University of California San Francisco
Co-authored papers 16
Yan Zeng
Department of Pharmacy, Affiliated Hospital of North Sichuan Medical College
Co-authored papers 14
Neil E Bhola
Zai Lab (US) LLC
Co-authored papers 9
Julie E Bauman
George Washington University
Co-authored papers 8
Umamaheswar Duvvuri
University of Pittsburgh School of Medicine
Co-authored papers 8
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 7
Lin Wang
Co-authored papers 7
Toni M Brand
University of Wisconsin School of Medicine and Public Health
Co-authored papers 5
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 4
Theresa M LaVallee
Parker Institute for Cancer Immunotherapy
Co-authored papers 3
Stefan Hartmann
University Hospital Wurzburg
Co-authored papers 3
Patrick Kwok-Shing Ng
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Patrick K Ha
University of California San Francisco
Co-authored papers 3
Simion I Chiosea
University of Pittsburgh
Co-authored papers 3
Rachel A O'Keefe
University of California San Francisco
Co-authored papers 3
Mi-Ok Kim
University of California san francisco
Co-authored papers 3
Max V Ranall
University of California San Francisco
Co-authored papers 3
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 3
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 3
Ann Marie Egloff
Harvard Medical School, Brigham and Women's Hospital
Co-authored papers 3
Zhenghe Wang
Co-authored papers 2
Yiling Lu
Co-authored papers 2
Adam B Olshen
12224University of California san francisco
Co-authored papers 2
Danielle L Swaney
J. David Gladstone Institutes
Co-authored papers 2
Ritu Roy
University of California San Francisco.
Co-authored papers 2
Aaron Hechmer
University of California san francisco
Co-authored papers 2
Scott R VandenBerg
University of California san francisco
Co-authored papers 2
Peter S Hammerman
Novartis Institutes for BioMedical Research
Co-authored papers 2
Zhenlin Ju
Co-authored papers 2
Release 1.2